Search results
Results from the WOW.Com Content Network
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. [8] [9] In CLL, the bone marrow makes too many lymphocytes, which are a type of white blood cell. [8] [9] In patients with CLL, B cell lymphocytes can begin to collect in their blood, spleen, lymph nodes, and bone marrow.
After this therapy, patients are infused with their own or the donor's hematopoietic stem cells. One study reported a 3-year survival rate of 36% and another reported a median progression-free survival time (i.e. time disease does not worsen) of 11.2 months with a median overall survival time that was not reached after 54 months of follow-up. [26]
In children under 15 in first-world countries, the five-year survival rate is greater than 60% or even 90%, depending on the type of leukemia. For infants (those diagnosed under the age of 1), the survival rate is around 40%. [13] In children who are cancer-free five years after diagnosis of acute leukemia, the cancer is unlikely to return. [13]
Factors predisposing to this progression in CLL/SLL MBL include the expression of CD38 cell-surface glycoprotein on the monoclonal B-cells, deletion of the short arm of chromosome 17 in these cells, [4] high serum levels of beta-2 macroglobulin, [2] and circulating B cell levels >10x10 9 /L. [9] There is relatively little information on the ...
[25] [20] [26] [19] Some patients experienced complete responses with no detectable tumor remaining years after treatment. [18] In one clinical trials, among the 93 patients treated with TILs, 19 patients had complete remissions that lasted greater than 3 years. [17]
Alemtuzumab (Campath), an anti-CD52 monoclonal antibody that attacks white blood cells, has been used in treatment with greater success than previous options. [7] In one study of previously treated people with T-PLL, people who had a complete response to alemtuzumab survived a median of 16 months after treatment.
Survival rate is a part of survival analysis. It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy. The survival period is usually reckoned from date of ...
A 1999 US-based study of people with CLL's medical records observed a 5-year relative survival rate of 77%, and a 10-year relative survival rate of 69%. [25] After 11 years, the observed relative survival rate remained around 66%. [25] Poorer survival is correlated with advanced age and black race.